New Stock News | DeepSeek Reportedly Hires Hillhouse Venture Capital Partner Yan Wentao as Chief Financial Officer
According to people familiar with the matter, DeepSeek, a mainland AI startup preparing for an initial public offering (IPO), plans to hire Yan Wentao, a partner at Hillhouse Venture Capital, as its first Chief Financial Officer.
According to people familiar with the matter, DeepSeek, a mainland Chinese AI startup preparing for an initial public offering (IPO), plans to hire Yan Wentao, a partner at GL Ventures, as its first chief financial officer (CFO).
The appointment of Yan, who has dealmaking experience, would be an important step in DeepSeek's transformation. The company, originally a research-focused lab funded by its founder's hedge fund, is shifting toward a more conventional corporate structure. A CFO typically plays a central role in managing investor communications, financial controls, capital allocation, and the disclosure processes required for a listing.
According to Zero2IPO, a Chinese venture capital industry service provider, Yan Wentao was born in 1991, and his representative investment projects include AI developer and DeepSeek competitor MINIMAX (00100).
Related Articles

HK Stock Market Move | Siasun Robot&Automation concept stocks extend losses; Unitree's stock price approaches the 400 yuan mark; humanoid Siasun Robot&Automation rental prices plunge.

HK Stock Market Move | Dajin Heavy Industry (01081) fell over 6% again, hitting a new post-listing low; the stock has pulled back more than 30% over the past five trading days.

UBS Group AG: Resumes coverage of Regeneron Pharmaceuticals, Inc. (REGN.US) with a "Buy" rating; blockbuster drug Dupixent's potential is underestimated.
HK Stock Market Move | Siasun Robot&Automation concept stocks extend losses; Unitree's stock price approaches the 400 yuan mark; humanoid Siasun Robot&Automation rental prices plunge.

HK Stock Market Move | Dajin Heavy Industry (01081) fell over 6% again, hitting a new post-listing low; the stock has pulled back more than 30% over the past five trading days.

UBS Group AG: Resumes coverage of Regeneron Pharmaceuticals, Inc. (REGN.US) with a "Buy" rating; blockbuster drug Dupixent's potential is underestimated.






